Mavacamten (Dosage)

Mavacamten is an innovative treatment for obstructive hypertrophic cardiomyopathy that works by regulating the contractility of the heart muscle. Its metabolism is primarily dependent on CYP2C19, so genetic differences in this enzyme can influence drug exposure and the selection of the most appropriate dose.

Mavacamten is a medication used for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. It is a selective cardiac myosin inhibitor that reduces the hypercontractility of the heart muscle and can improve left ventricular outflow tract obstruction.

Treatment response may vary among individuals due to clinical and genetic factors. CYP2C19 is a liver enzyme involved in the metabolism of mavacamten.

Side effects

• Dizziness.
• Syncope.
• Reduced left ventricular ejection fraction.
• Systolic dysfunction.
• Fatigue.

Precautions

Mavacamten can reduce cardiac contractility and requires monitoring by echocardiography. Patients with reduced CYP2C19 activity may experience slower elimination and increased drug exposure.

Drug interactions

Mavacamten is primarily metabolized by CYP2C19 and CYP3A4. Inhibitors of these enzymes may increase its plasma concentrations, while inducers may reduce its exposure and efficacy.

Brand names

• Camzyos®